azacitidine has been researched along with Tuberous Sclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gallacher, J; Kalogerou, M; Sampson, JR; Shen, MH; Yang, J | 1 |
1 other study(ies) available for azacitidine and Tuberous Sclerosis
| Article | Year |
|---|---|
Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
Topics: Animals; Azacitidine; Blotting, Western; Catecholamine Plasma Membrane Transport Proteins; Decitabine; Disease Models, Animal; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Hypoglycemic Agents; Immunohistochemistry; Kidney; Kidney Neoplasms; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; Mice, Knockout; Multiprotein Complexes; Organic Cation Transport Proteins; Organic Cation Transporter 2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis; Tuberous Sclerosis Complex 1 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2013 |